{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Sama S"],"pubmed_abstract":["Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of <i>CDKN2A</i>, <i>TP53</i>, <i>CDKN2B</i>, <i>BAP1</i>, etc. These mutations are involved in the transformation of low-grade tumors to high-grade tumors, presenting a vital tool f"],"journal":["World journal of oncology"],"pagination":["1-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8913015"],"repository":["biostudies-literature"],"pubmed_title":["Advances in the Treatment of Mucoepidermoid Carcinoma."],"pmcid":["PMC8913015"],"pubmed_authors":["Komiya T","Guddati AK","Sama S"],"additional_accession":[]},"is_claimable":false,"name":"Advances in the Treatment of Mucoepidermoid Carcinoma.","description":"Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of <i>CDKN2A</i>, <i>TP53</i>, <i>CDKN2B</i>, <i>BAP1</i>, etc. These mutations are involved in the transformation of low-grade tumors to high-grade tumors, presenting a vital tool f","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-26T12:56:33.189Z","creation":"2024-11-07T10:55:53.714Z"},"accession":"S-EPMC8913015","cross_references":{"pubmed":["35317327"],"doi":["10.14740/wjon1412"]}}